855-6-RxLink	Strategic Pharmacy Business Initiative
	RxLink - Spirit of the Pharmacist! Pharmacy News Drug Updates HMO News Events for Pharmacists Clinical Pharmacy Compounding Pharmacy HomeCare Pharmacy Long-Term Care  RxLink Nutrition Registration Pharmacy Staffing Pharmacy Affiliates Independent Voices E-mail us Feedback to RxLink Consulting Services Contact RxLink RxLink Archives RxLink®	RxLink® The #1 Link for Pharmacy Students My Father's Pharmacy                               Pacific School of Pharmacy  02 As I relaxed in an old swarthy chair, in the corner of my father's pharmacy, I stuffed an orange gummy bear into my chubby round face. I listened to my father speak in Cantonese to a patient about over the counter drugs. Shortly after, my father spoke to another patient this time in English, inquiring about a prescription drug. I watched as both patients strolled out of the pharmacy with grins on their faces. By the looks on their faces, it was apparent that the customers always left more rejuvenated and pleased than when they walked in. Patients praised my father for his dedication, professionalism and most importantly-ability to communicate. My fondest childhood memories were spending time in my father's pharmacy. As a child, I grew up working at my father's side. I discovered quite early what the life of a pharmacist was like. My father's job as a pharmacist never constituted just distributing medicine; he was an integral part of the medical team. Professionalism as well as communication plays as important role in the pharmaceutical profession, between the patients, doctors, nurses, and other pharmacists. I always felt that my father had an advantage over other pharmacists by being fluent in two languages. His bilingual ability raised the standards in his independent pharmacy. He brought confidence to his patients and demonstrated professionlism in a caring way. Presently, I also wish to pursue the same profession as my father. I hope to contribute to the pharmaceutical profession with the ability to speak not only two but three languages. As one of my prized attributes, I enjoy interacting and communicating with others. With this strong desire, I am eager to cousel with the knowledge I am attaining in pharmacy school and continued education. Couseling will not only include the basic over the counter drugs as well as prescription drugs, but also the knowledge acquired in my continued education. Finally, having the ability to warmly communicate with my patients will ensure the trust needed for professionalism and success. My father's abilities as a pharmacist has far surpassed his own expectations. I feel my passion for pharmaceutical care, hard work, and dedication can and will do the same. Pharmacy Student...                                                     RxLink® August 2004 From: Merck / Schering-Plough Pharmaceuticals Dear Pharmaceutical Purchaser:              Merck/Schering-Plough Pharmaceuticals (MSP) is pleased to introduce VYTORIN (ezetimibe/simvastatin) Tablets, the first and only product that inhibits both cholesterol production and intestinal absorption. VYTORIN contains both the HMG-CoA reductase inhibitor (statin) simvastatin and the cholesterol absorption inhibitor ezetimibe. Merck/Schering-Plough Pharmaceuticals is a joint venture between Merck & Co., Inc., and Schering-Plough Corporation that develops and markets prescription cholesterol-management medicines in the United States. In a multicenter, double-blind, placebo-controlled, 12-week study of 1,528 patients with hypercholesterolemia, VYTORIN lowered LDL-C by 52% at the recommended starting dose (10/20 mg) and 60% at the maximum dose (10/80 mg). VYTORIN is also indicated for the reduction of elevated TOTAL-C and LDL_C in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia when diet alone is not enough. VYTORIN is also indicated for the reduction of elevated TOTAL-C and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to to other lipid-lowering treatments (eg, LDL apheresis), or if such treatments are unavailable. VYTORIN is available in 4 dosage strengths, each containing 10 mg of ezetimibe and 10 mg, 20 mg, 40 mg, or 80 mg of simvastin. VYTORIN should be taken as a single dose in the evening with or without food. VYTORIN is contraindicated in patients with hypersensitivity to any component of this medication; active liver disease; unexplained persistent elevations of serum transaminases; women who are of child-bearing age (unless highly unlikely to conceive), nursing, or pregnant. To place an order, please contact your wholesaler. If you have any questions, please contact the Merck Pharmacy/Wholesaler National Account Executive or Schering-Plough Trade Director who is responsible for your account. For any additional questions, please contact the MSP National Service Center at 1-866-637-2501. Enclosed is the press release announcing the approval of VYTORIN. Before Dispensing VYTORIN, please read the enclosed Prescribing Information. Sincerely, Adam H. Schnechter Vice President and General Manager Merck/Schering-Plough Pharmaceuticals Back to Previous Page ©2004 RxLink The Pharmaceutical Care Network!